Disseminated aspergillosis in an adolescent with acute lymphoblastic leukemia

Pediatric Blood and Cancer

Volumn 51, Issue 3, 2008, Pages 423-426

  Zwitserloot, Annelies M ^a   Warris, Adilia ^a   Van't Hek, Louis G ^a   Van Die, Lya E ^a   Verweij, Paul E ^a   Mavinkurve Groothuis, Annelies M C ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Caspofungin; Disseminated aspergillosis; Oncology; Pediatric; Voriconazole

Indexed keywords

ASPARAGINASE; C REACTIVE PROTEIN; CASPOFUNGIN; CEFTAZIDIME; CREATININE; CYTARABINE; DAUNORUBICIN; MERCAPTOPURINE; METHOTREXATE; PREDNISOLONE; PREDNISONE; TEICOPLANIN; VINCRISTINE; VORICONAZOLE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; ASPERGILLOSIS; BLOOD LEVEL; BONE MARROW BIOPSY; BRAIN ASPERGILLOSIS; BRONCHOSCOPY; CANCER CHEMOTHERAPY; CASE REPORT; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG MEGADOSE; DRUG WITHDRAWAL; FEMALE; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; HUMAN TISSUE; HYPERGLYCEMIA; HYPERTENSION; KIDNEY BIOPSY; LABORATORY TEST; LUNG ASPERGILLOSIS; MYCOSIS; NEPHROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RESPIRATORY FAILURE; THORAX RADIOGRAPHY; THYROID ASPERGILLOSIS;

ADOLESCENT; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; CENTRAL NERVOUS SYSTEM FUNGAL INFECTIONS; ECHINOCANDINS; FEMALE; HUMANS; LUNG DISEASES, FUNGAL; OPPORTUNISTIC INFECTIONS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PYRIMIDINES; THYROID DISEASES; TOMOGRAPHY, X-RAY COMPUTED; TRIAZOLES;

EID: 48249083415     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21601     Document Type: Article

References (20)

1. Jantunen E, Ruutu P, Piilonen A, et al. Treatment and outcome of invasive Aspergillus infections in allogeneic BMT recipients. Bone Marrow Transplant 2000;26:759-762.
2. Kirkpatrick WR, Perea S, Coco BJ, et al. Efficacy of caspofungin alone and in combination with voriconazole in a Guinea pig model of invasive aspergillosis. Antimicrob Agents Chemother 2002;46: 2564-2568.
3. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: Systematic review of the literature. Clin Infect Dis 2001;32:358-366.
4. Schwartz S, Ruhnke M, Ribaud P, et al. Improved outcome in central nervous system aspergillosis, using voriconazole treatment. Blood 2005;106:2641-2645.
5. Abbasi S, Shenep JL, Hughes WT, et al. Aspergillosis in children with cancer: A 34-year experience. Clin Infect Dis 1999;29:1210-1219.
6. Dotis J, Iosifidis E, Roilides E. Central nervous system aspergillosis in children: A systematic review of reported cases. Int J Infect Dis 2007;11:381-393.
7. Groll AH, Kurz M, Schneider W, et al. Five-year-survey of invasive aspergillosis in a paediatric cancer centre. Epidemiology, management and long-term survival. Mycoses 1999;42:431-442.
8. Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus. Clin Infect Dis 2002;34:7-14.
9. Goldani LZ, Zavascki AP, Maia AL. Fungal thyroiditis: An overview. Mycopathologia 2006;161:129-139.
10. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347:408-415.
11. Hajdu R, Thompson R, Sundelof JG, et al. Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872). Antimicrob Agents Chemother 1997;41:2339-2344.
12. Lutsar I, Roffey S, Troke P. Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients. Clin Infect Dis 2003;37:728-732.
13. Kartsonis NA, Saah AJ, Joy LC, et al. Salvage therapy with caspofungin for invasive aspergillosis: Results from the caspofungin compassionate use study. J Infect 2005;50:196-205.
14. Maertens J, Raad I, Petrikkos G, et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004;39:1563-1571.
15. Cesaro S, Giacchino M, Locatelli F, et al. Safety and efficacy of a caspofungin-based combination therapy for treatment of proven or probable aspergillosis in pediatric hematological patients. BMC Infect Dis 2007;7:28.
16. Maertens J, Glasmacher A, Herbrecht R, et al. Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis. Cancer 2006;107:2888-2897.
17. Marr KA, Boeckh M, Carter RA, et al. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 2004;39:797-802.
18. von Mach MA, Burhenne J, Weilemann LS. Accumulation of the solvent vehicle sulphobutylether beta cyclodextrin sodium in critically ill patients treated with intravenous voriconazole under renal replacement therapy. BMC Clin Pharmacol 2006; 6:6.
19. FDA. Antiviral Drugs Advisory Committee - Briefing Document for Voriconazole (Oral and Intravenous Formulations). http:// www.fda.gov/ohrms/ dockets/ac/01/briefing/3792b2_01_Pfizer. pdf.
20. Woods G, Miceli MH, Grazziutti ML, et al. Serum Aspergillus galactomannan antigen values strongly correlate with outcome of invasive aspergillosis: A study of 56 patients with hematologic cancer. Cancer 2007;110:830-834.